Chemed (CHE) Q3 2026 Earnings Call Transcript

Chemed reported Q3 2026 revenue of $690.9 million, up 10.6%, and adjusted diluted EPS of $6.75, up 28.1%; management expects full-year adjusted EPS to finish at or slightly above the high end of prior guidance. VITAS revenue rose 12.2% to $457.4 million, while adjusted EBITDA excluding Medicare cap effects increased 31.4% to $92.5 million. Roto-Rooter revenue grew 7.5%, but adjusted EBITDA fell 2.5% to $48.2 million as marketing and fuel costs pressured margins. Chemed spent $62.5 million to reacquire California franchise territories and repurchased 125,000 shares for $66 million during the quarter.

Analysis

The earnings mix is more fragile than the consolidated growth headline implies. VITAS is carrying near-term profit momentum, but some margin expansion reflects tight staffing and back-office cost control; as census grows, hiring and wage costs may normalize before reimbursement catches up. The shorter length of stay also makes admission volume and referral mix important leading indicators: sustained growth needs conversion and care capacity, not just more starts. Florida’s cap cushion is supportive, but it does not eliminate exposure in other programs or future cap years.

Roto-Rooter’s growth is strategically valuable but currently less earnings-accretive than the owned-branch base. Acquisitions add revenue before operational improvements arrive, while rising paid-search costs and fuel pressure margins. A 12–18 month integration window means reported margin recovery is a 2027 execution test, not an immediate earnings catalyst. Alphabet may benefit marginally from higher search bidding, but this is not a material standalone thesis for GOOG; AI-driven discovery could also alter lead economics over time.

Near term, the guidance signal supports CHE, but the upside is partly offset by expected fourth-quarter Roto-Rooter headwinds. Over 1–3 months, watch paid-lead mix/cost, VITAS staffing expense, and audit-related contra-revenue. Over 6–18 months, the key test is whether acquired territories approach branch economics without sacrificing organic lead generation. The contrarian risk is treating VITAS’ exceptional margin and group EPS growth as fully repeatable; valuation and post-call price action are needed before sizing a chase.

Key Decisions for Investors

• CHE: avoid chasing an earnings-gap move without valuation context; consider a staged long on post-event weakness if VITAS census growth remains broad-based and the company holds its full-year EPS outlook. Falsify if VITAS margin contracts on staffing costs or guidance is cut.
• Treat Roto-Rooter acquisitions as a medium-term integration option, not a near-term margin catalyst. Track paid leads as a share of total leads, marketing expense, and acquired-territory EBITDA over the next 2–4 quarters; pause adding if lead costs rise while same-store growth decelerates.
• Do not short GOOG on this evidence: incremental search monetization is likely too small to matter to Alphabet, while AI-led search changes create an uncertain offset. Revisit only with evidence of a material change in advertiser economics or search monetization.
• Monitor VITAS audit activity and Medicare cap outcomes separately by program. A sustained rise in revenue reviewed or adverse reimbursement outcomes—not audit volume alone—would weaken the quality of reported growth.